Prolonged Clinical Remission in Patients with Systemic Lupus Erythematosus
Authors:
- Murray B. UrowitzMUMurray B. Urowitz
- Dominique IbañezDIDominique Ibañez
- Anjali PapnejaAPAnjali Papneja
- Dafna D. GladmanDGDafna D. Gladman
- 1 August 2014
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 41 (9) , 1808-1816
Abstract
Objective.: Systemic lupus erythematosus (SLE) is typically a relapsing/remitting disease. However, some patients experience prolonged remission. These patients may provide further insights into SLE pathophysiology. In this study we characterize their clinical course.Methods.: Prolonged remission was defined as Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) = 0, = 2, or = 4 (based on serology) for ≥ 5 consecutive years, with visits ≤ 18 months apart. The patients could be taking antimalarials, but not corticosteroids or immunosuppressives. Flare was defined as clinical activity on SLEDAI-2K, or by corticosteroid/immunosuppressive initiation. Each patient’s preremission course was classified as monophasic, relapsing/remitting, or chronic active. These patients were compared to matched SLE controls and patients achieving remission on medications.Results.: A total of 38/1613 (2.4%) patients achieved prolonged remission while taking no medications. The mean duration was 11.5 ± 6.4 years. Twenty-seven patients (71.0%) had relapsing/remitting disease, 11 (28.9%) had monophasic illness, and none had chronic active disease prior to remission. They differed from matched controls in ethnicity, disease activity at first visit, and cumulative organ damage. There were 34/1613 patients (2.1%) who achieved prolonged remission while taking steroids and/or immunosuppressives, with mean duration 8.5 ± 2.9 years. Twelve patients (35.3%) experienced disease flare. They were younger at diagnosis, with more disease activity prior to remission than patients taking no medications.Conclusion.: Prolonged remission is an infrequent outcome among patients and is preceded by an atypically monophasic clinical course in a significant minority. Those taking medications represent a heterogeneous group: those who will tolerate eventual taper, and those whose disease activity was merely suppressed by ongoing immunosuppression. Prolonged remission may reflect unique pathophysiologic mechanisms, and warrants further investigation.Keywords
This publication has 31 references indexed in Scilit:
- Flare, Persistently Active Disease, and Serologically Active Clinically Quiescent Disease in Systemic Lupus Erythematosus: A 2-Year Follow-Up StudyPLOS ONE, 2012
- TLR Tolerance Reduces IFN-Alpha Production Despite Plasmacytoid Dendritic Cell Expansion and Anti-Nuclear Antibodies in NZB Bicongenic MicePLOS ONE, 2012
- 52-Year-Old Man With Arthralgias, Fever, and FatigueMayo Clinic Proceedings, 2010
- Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosusLupus, 2010
- Understanding the Epidemiology and Progression of Systemic Lupus ErythematosusSeminars in Arthritis and Rheumatism, 2010
- Predictors of disease course and remission in systemic juvenile idiopathic arthritis: Significance of early clinical and laboratory featuresArthritis & Rheumatism, 2006
- Late-Onset Systemic Lupus ErythematosusMedicine, 2004
- Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation1Rheumatology, 1999
- High disease activity at baseline does not prevent a remission in patients with systemic lupus erythematosusRheumatology, 1999
- Remission of Systemic Lupus ErythematosusMedicine, 1996